Results 51 to 60 of about 2,707 (157)

Is Mycobacterial InhA a Suitable Target for Rational Drug Design?

ChemMedChem, Volume 20, Issue 13, July 1, 2025.
InhA is the target of isoniazid, a first‐line antituberculosis drug. Isoniazid is, in fact, a prodrug that needs to be activated. Researchers are trying to develop direct inhibitors of InhA. This includes the resolution of crystallographic structures. The Protein Data Bank contains over a hundred InhA structures.
Julien Rizet, Laurent Maveyraud, David Rengel, Valérie Guillet, Gabriel Publicola, Frédéric Rodriguez, Christian Lherbet, Lionel Mourey   +7 more
wiley   +1 more source

New drugs in the treatment of drug-resistant tuberculosis in children. Experience with the use of delamanid in combination with bedaquiline

Journal of Global Antimicrobial Resistance
OBJECTIVE: To determine the safety and effectiveness of delamanid in combination with bedaquiline in children for the treatment of multidrug-resistant tuberculosis. MATERIALS-METHODS: In 2023-2024, 18 children aged 3 to 17 years with MDR-TB were treated.
Ekaterina Sokolskaya, Nadezhda Klevno, Anastasiya Samoylova, Alexey Kazakov, Anastasiya Gaida   +4 more
doaj   +1 more source

Machine Learning‐Based High‐Throughput Screening, Molecular Modeling and Quantum Chemical Analysis to Investigate Mycobacterium tuberculosis MetRS Inhibitors

ChemistryOpen, Volume 14, Issue 7, July 2025.
This paper provides a comprehensive approach using the ChEMBL database to construct a machine learning model that screened 10 million compounds from the eMolecules database. Two promising inhibitors targeting Mycobacterium tuberculosis methionyl‐tRNA synthetase were identified.
Rajesh Maharjan, Kalpana Gyawali, Arjun Acharya, Madan Khanal, Kamal Khanal, Mohan Bahadur Kshetri, Madhav Prasad Ghimire, Tika Ram Lamichhane   +7 more
wiley   +1 more source

Effectiveness and safety of regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis

Perspectives in Clinical Research
Background: Bedaquiline and delamanid have been included in the individualized treatment regimen (ITR) to treat patients with drug-resistant tuberculosis (DR-TB).
Oki Nugraha Putra, Yulistiani Yulistiani, Soedarsono Soedarsono, Susi Subay   +3 more
doaj   +1 more source

Establishing the Exposure‐QT Relationship During Bedaquiline Treatment Using a Time‐Varying Tuberculosis‐Specific Correction Factor (QTcTBT)

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 7, Page 1252-1261, July 2025.
ABSTRACT Evaluating QT prolongation induced by anti‐tuberculosis (TB) drugs in patients with active TB, who often experience tachycardia, is challenging due to the limitations of Fridericia's correction factor (QTcF) in decorrelating QTc from heart rate (HR).
Thanakorn Vongjarudech, Anne‐Gaëlle Dosne, Bart Remmerie, Mats O. Karlsson, Elin M. Svensson   +4 more
wiley   +1 more source

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis

Emerging Infectious Diseases, 2017
We report the experiences of 5 patients taking bedaquiline with delamanid in combination: 1 patient was cured; 3 culture converted, with 2 continuing and 1 changing therapy; and 1 died from respiratory insufficiency.
Andrey Maryandyshev, Emanuele Pontali, Simon Tiberi, Onno Akkerman, Shashank Ganatra, Tsetan Dorji Sadutshang, Jan-Willem Alffenaar, Rohit Amale, Jai Mullerpattan, Sonam Topgyal, Zarir Farokh Udwadia, Rosella Centis, Lia D’Ambrosio, Giovanni Sotgiu, Giovanni Battista Migliori   +14 more
doaj   +1 more source

Functionalized Polydopamine Nanoparticles: A Promising Drug Delivery Platform for the Treatment of Tuberculosis

Drug Development Research, Volume 86, Issue 4, June 2025.
ABSTRACT Tuberculosis (TB) is considered a major infectious disease by the World Health Organization. The WHO estimates that there are 1.8 million TB deaths, and 10.4 million new cases of the disease reported yearly. While there are conventional therapies for TB, they have drawbacks such as a lengthy pill regimen, rigorous scheduling, and protracted ...
Nnamdi Ikemefuna Okafor, Precious Nnaji, Ngozi Francisca Nnolum‐Orji, Yahya E. Choonara   +3 more
wiley   +1 more source

Novel Metronidazole Conjugates as Antimicrobial Agents

Drug Development Research, Volume 86, Issue 4, June 2025.
ABSTRACT Metronidazole (MTZ) is one of the oldest and still used anti‐infective nitroimidazole group drug. Although it is effective against anaerobic bacteria, protozoa, and parasites in clinical settings, it lacks efficacy against aerobic microorganisms.
Erol Akgün, Melike Demirayak, Leyla Yurttaş, Ülkiye Dudu Gül, Şeref Demirayak   +4 more
wiley   +1 more source

Mathematical Analysis of the Transmission Dynamics of Malaria and Tuberculosis Co‐Infection With Control Strategies

Engineering Reports, Volume 7, Issue 6, June 2025.
ABSTRACT Co‐infections such as malaria and tuberculosis pose significant public health challenges, particularly in regions where both diseases are endemic. Despite the global burden of these infections, their combined transmission dynamics remain poorly understood, highlighting the importance of this study. We develop a comprehensive mathematical model
Benedict Celestine Agbata, Erjola Cenaj, Dennis Ferdinand Agbebaku, Obiora Cornelius Collins, Raimonda Dervishi, Homan Emadifar, Azuka Uzoamaka Ezeafulukwe, Godwin Christopher Ezike Mbah   +7 more
wiley   +1 more source

Continuous Flow Technology Enabling Photochemistry

Advanced Synthesis &Catalysis, Volume 367, Issue 9, May 6, 2025.
Abstract The merger of continuous flow technology and modern photochemistry has enabled countless applications showcasing new opportunities for chemical synthesis demonstrating improvements in selectivity, safety, sustainability and scalability. This focused review aims to highlight a selection of recently published case studies from academic and ...
Ruairi Crawford, Marcus Baumann
wiley   +1 more source